Anders Ekblom
Independent Non-Executive DirectorDr. Anders Ekblom, M.D., Ph.D., D.D.S., serves as Independent Director at Flerie AB (publ) (Formerly Flerie Invest AB) since 2023. He had been Independent Non-Executive Chairman of Alligator Bioscience AB (publ) since June 1, 2021 until May 7, 2025. He also serves as Chairman at Xspray Pharma AB (publ) since May 20, 2021. Dr. Ekbolm serves as Senior Advisor at Phase4 Partners Limited. Dr. Ekbolm is an Associate Professor at Karolinska Institutet. He is Director of Flerie Invest AB from August 19, 2025. Dr. Ekblom served as Vice Chairman of the Board at LEO Pharma A/S since August 1, 2021 until April 2022. Dr. Ekblom served as Interim Chairman of the Board at LEO Pharma A/S since May 7, 2021 until August 1, 2021. Dr. Ekblom served as Vice Chairman of the Board at LEO Pharma A/S since March 2019 until May 7, 2021. He served as an Industrial Advisor at Ratos AB (publ) since 2019. Products, projects, productivity and change management. He has managed staff and projects in United States, European Union and Asia. He was a Member of Global Executive Teams holding different senior roles including Executive Vice President of Global Medicines Development, Global Head Clinical Development, Global Therapy Area Head, Global Head Science and Technology Integration and Chief Executive Officer at AstraZeneca AB. He served as the Chief Executive Officer of AstraZeneca Sweden. He served as an Executive Vice President of Global Medicines Development at AstraZeneca plc since January 1, 2009. At AstraZeneca, he was responsible for the global clinical development function, delivering across all clinical stages of drug development including lifecycle management and leading staff at all major R&D sites. He also served as an Executive Vice President of Development of AstraZeneca PLC since January 01, 2009. He was Chairman of TFS Trial Form Support International AB until 2019. He serves as the Chairman of the Board at Karolinska University Hospital and a Non-Executive Board Member of several biotech companies. He serves as an Independent Non-Executive Director of Mereo BioPharma Group Plc since July 29, 2015. He has been a Non-Executive Director of Alligator Bioscience AB (publ) since May 2, 2017. He served as Chairman of the Board at Elypta AB since 2019 until 2024 and served as its Director since February 2018 until 2024. He serves as a Board Member at LEO Pharma A/S since 2018. He served as an Independent Director at Medivir AB since May 8, 2014. He had been a Director at AnaMar AB and Infant Bacterial Therapeutics AB (publ) since 2014 until May 06, 2019. He served as a Director of Albireo AB. He was recognized as one of the 100 best Managers in Pharma Industry by PharmaVOICE in 2006. He has 60 scientific publications in peer reviewed journals and additional publications such as book chapters. He is a Fellow of the Royal Swedish Academy of Engineering Sciences. He is a physician. Dr. Ekblom is Board Certified Medical Doctor in Anaesthesiology and Intensive Care and Associate Professorship in Physiology from the Karolinska Institute, Stockholm. He serves as Board Member at NxtScience AB. Dr. Ekblom holds a M.D., Ph.D. in Physiology and a D.D.S. from Karolinska Institutet.
Positions
- Company NameMereo BioPharma Group plcStock CodeMREOPositionIndependent Non-Executive DirectorColleagues
- DVDenise Vera Scots-KnightCo-Founder, CEO & Executive Director
- MSMichael Stephen WyzgaIndependent Non-Executive Chairman of The Board
- CECharles Edward SermonCo-Founder, General Counsel, Business Development & Company Secretary
- CFChristine FoxChief Financial Officer
- JAJohn A. LewickiChief Scientific Officer
- BLBal LallyVP & Head of HR
- DRDeepika Rachel PakianathanIndependent Non-Executive Director
- JBJeremy BenderIndependent Non Executive Director
